证券日报网讯 12月17日，仙琚制药在互动平台回答投资者提问时表示，董事会换届选举人选综合考量 合规性、专业性与治理效能，兼顾性别、年龄、专业背景多元化，同时对履职能力要求能投入足够时间 精力，具备决策、统筹、公司治理等能力，兼顾管理团队稳定性。 （文章来源：证券日报） ...

格隆汇12月17日丨仙琚制药(002332.SZ)在投资者互动平台表示，克拉司酮原料药尚在国内申报准备阶 段。 （原标题：仙琚制药(002332.SZ)：克拉司酮原料药尚在国内申报准备阶段） ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation for the quality and efficacy of Nicardipine Hydrochloride Injection, which is expected to enhance the product's market competitiveness and accumulate experience for future evaluations [1][4]. Group 1: Drug Information - The drug Nicardipine Hydrochloride Injection is a calcium channel blocker primarily used for rapid blood pressure reduction and managing acute hypertension situations, such as during surgery or in emergency settings [3]. - The approved specifications for Nicardipine Hydrochloride Injection are 10ml:10mg (approval number H20258264) and 5ml:5mg (approval number H20258265), with the product adhering to the national drug registration standard YBH32372025 [3]. Group 2: Approval Details - The approval for the drug was granted based on the regulations outlined in the Drug Administration Law of the People's Republic of China and related announcements, allowing the addition of 5ml:5mg and 10ml:10mg specifications [2].

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

盐酸尼卡地平注射液是一种钙离子拮抗剂药物，主要用于快速降低血压和处理急性高血压情况，如手术 中或急诊环境。它通过扩张血管来促进血流，保护心、脑、肾等重要器官，效果迅速但需在医生监控下 使用。 格隆汇12月9日丨仙琚制药(002332.SZ)公布，公司于近日收到国家药品监督管理局核准签发的关于盐酸 尼卡地平注射液的《药品补充申请批准通知书》（通知书编号：2025B05803 和 2025B05804），公司盐 酸尼卡地平注射液通过仿制药质量和疗效一致性评价。 ...

仙琚制药公告，公司于近日收到国家药品监督管理局核准签发的关于盐酸尼卡地平注射液的《药品补充 申请批准通知书》，公司盐酸尼卡地平注射液通过仿制药质量和疗效一致性评价。 ...

仙琚制药12月9日公告，公司近日收到国家药品监督管理局核准签发的关于盐酸尼卡地平注射液的《药 品补充申请批准通知书》，公司盐酸尼卡地平注射液通过仿制药质量和疗效一致性评价。盐酸尼卡地平 注射液是一种钙离子拮抗剂药物，主要用于快速降低血压和处理急性高血压情况，如手术中或急诊环 境。它通过扩张血管来促进血流，保护心、脑、肾等重要器官，效果迅速但需在医生监控下使用。 ...

证券代码：002332 证券简称：仙琚制药 公告编号：2025-056 盐酸尼卡地平注射液是一种钙离子拮抗剂药物，主要用于快速降低血压 和处理急性高血压情况，如手术中或急诊环境。它通过扩张血管来促进血流， 保护心、脑、肾等重要器官，效果迅速但需在医生监控下使用。 浙江仙琚制药股份有限公司 关于盐酸尼卡地平注射液通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局核准签发的关于盐酸尼卡地平注射液的《药品补充申请批准通知 书》（通知书编号：2025B05803 和 2025B05804），公司盐酸尼卡地平注射 液通过仿制药质量和疗效一致性评价。现将相关情况公告如下： 申请内容：申报仿制药质量和疗效一致性评价。 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药 品医疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质 量和疗效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药 监局关于开展化学药品注射剂仿制药质量和疗效一致性 ...

证券日报网讯12月3日，仙琚制药（002332）在互动平台回答投资者提问时表示，公司大股东始终关注 市值管理与公司长期发展，履行股东职责，通过定期沟通、专项研讨等方式，督促管理层聚焦主营业 务、优化经营、加强投资者关系等工作，以稳健的业绩为市值稳定提供坚实支撑。 ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].